middle.news
How Recce’s $15.8M Raise Fuels Phase 3 Trial Expansion in Indonesia
7:01am on Friday 1st of August, 2025 AEST
•
Healthcare
Read Story
How Recce’s $15.8M Raise Fuels Phase 3 Trial Expansion in Indonesia
7:01am on Friday 1st of August, 2025 AEST
Key Points
Phase 3 clinical trial sites expanded in Indonesia for diabetic foot infections
Additional Phase 2 approval broadens patient access to RECCE 327 Topical Gel
New Cooperative Research Agreement with US Army’s infectious disease institute
Completed $15.8 million capital raise from existing shareholders
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE